This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cardinal, H. Articles by D’Amour, P. Search for Related Content PubMed PubMed Citation Articles by Cardinal, H. Articles by D’Amour, P.

The Set Point of Parathyroid Hormone Stimulation by Calcium Is Normal in Progressive Renal Failure

Centre Hospitalier de l’ Université de Montréal Research Center, Saint-Luc Campus, and Departments of Medicine and Biochemistry, University of Montreal, Montreal, Quebec H2X 1P1, Canada

Address all correspondence and requests for reprints to: Pierre D’Amour, M.D., Centre de recherche du Centre Hospitalier de l’ Université de Montréal, Campus Saint-Luc, 264 René Lévesque Boulevard East, Montreal, Quebec H2X 1P1, Canada.

An increased set point of PTH stimulation by ionized calcium (Ca⁺⁺) has been observed in renal failure patients with severe secondary hyperparathyroidism. The extension of this concept to all renal failure patients has remained problematic, even if it could explain elevated PTH levels in the absence of other biochemical abnormalities. We were particularly interested in seeing whether the concept could fit patients with progressive renal failure (PRF). To achieve this, we studied 26 normals (N), 9 patients with PRF, and 12 hemodialyzed patients (HD) in the basal state and during parathyroid function tests. The latter two groups were studied at the end of winter and end of summer, respectively. Patients with PRF had normal levels of Ca⁺⁺, PO₄, and 1,25(OH)₂D, and they had low-normal concentrations of 25(OH)D; their basal I- and C-PTH levels were 3- and 4-fold higher than N, as were their creatinine levels. HD had significantly lower levels of Ca⁺⁺ and 1,25(OH)₂D, and they had higher levels of phosphate, creatinine, I-PTH, and C-PTH than N or PRF. Stimulated levels of I-PTH were similar in N (13.6 ± 4.3 pmol/L) and PFR (18 ± 3.3 pmol/L) and elevated in HD (37.1 ± 28.7 pmol/L; P < 0.001 vs. N, and P < 0.05 vs. PRF). Nonsuppressible I-PTH was increased 2-fold in PRF (N = 0.64 ± 0.19 vs. PRF = 1.28 ± 0.46 pmol/L; P < 0.01) and 6-fold in HD (3.95 ± 2.85 pmol/L; P < 0.001 vs. others). But the set point of I-PTH stimulation by Ca⁺⁺ was normal in PRF (N = 1.18 ± 0.03 vs. PRF = 1.20 ± 0.04 mmol/L; not significant) and decreased in HD (1.09 ± 0.04 mmol/L; P < 0.001 vs. others). Similar results were obtained with the set point of C-PTH and of the C-PTH/I-PTH ratio. A positive correlation was observed between serum Ca⁺⁺ concentration and the set point value when all three populations were analyzed together (r = 0.759, n = 47, P < 0.0001). These results indicate that the set point of PTH stimulation is normal in PRF and decreased in hypocalcemic HD. The set point seems to adjust to the ambient Ca⁺⁺ concentration of the patients, by mechanisms yet to be elucidated. This does not suggest participation of this factor to the genesis of the secondary hyperparathyroidism of PRF.

This article has been cited by other articles:

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]

				S Bas, E Aguilera-Tejero, A Bas, J C Estepa, I Lopez, J A Madueno, and M Rodriguez The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve J. Endocrinol., January 1, 2005; 184(1): 241 - 247. [Abstract] [Full Text] [PDF]

				W. G. Goodman Medical management of secondary hyperparathyroidism in chronic renal failure Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii2 - 8. [Abstract] [Full Text] [PDF]

				Y. Imanishi, H. Tahara, N. Palanisamy, S. Spitalny, I. B. Salusky, W. Goodman, M. L. Brandi, T. B. Drueke, E. Sarfati, P. Urena, et al. Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of Uremia J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1490 - 1498. [Abstract] [Full Text] [PDF]